DISRUPT: Aim 2

That Black, Indigenous, and People of Color (BIPOC) are more likely to die from their cancer is well known. Despite years of progress in cancer research and treatment, most research is done in white populations. For this reason, it is not certain how best to treat BIPOC with cancer. The number of people with cancer who join a clinical trial (CT) in the United States at 8%. This low number is due to many reasons including the things related to the healthcare system, the number and type of clinical trials that are available, and the other illnesses patients have. These factors affect BIPOC patients from low-income communities more often than non-Hispanic white people. The purpose of this clinical trial is to test the effectiveness of an intervention to increase clinical trial enrollment, particularly among BIPOC patients with cancer. This intervention includes providing patients with breast, prostate, or liver cancer with general education about clinical trials prior to their first oncology visit to empower patients to engage their cancer care provider in discussions about cancer clinical trial participation. Additionally, this intervention will generate lists of trials at 3 New York City cancer centers involved in this multisite study for which the patient is potentially eligible. These “match” lists will be distributed to both the patient and the cancer care provider at key treatment decision-making timepoints to stimulate conversation and facilitate referral to a cancer clinical trial. Outcomes of this clinical trial include documented conversations between patients and their cancer care provider about cancer clinical trial participation, number of patients enrolled onto a cancer clinical trial, and identification of situations where no trial is available for the patient. Both patients and providers will be asked to complete a baseline and follow-up survey to evaluate knowledge, attitudes, and behaviors related to clinical trial enrollm

Are you Eligible? (Inclusion Criteria)

• Cancer care providers: physicians, nurse practitioners, residents, and fellows involved in the care of patients with breast, prostate, and liver cancer. Patients:
• All new adult patients (18 years or older) diagnosed with breast, prostate, or liver cancer.
• Adult patients diagnosed with breast, prostate, or liver cancer and who previously completed primary treatment, are not on active cancer treatment for the past 6 months and did not see the oncologist in > 6months and < 12 months who are likely presenting with recurrence or disease progression.